SCHEMBL9760948

SCHEMBL9760948

NCCCCCCc1nc(N2CCOCC2)c([N+](=O)[O-])[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.36
CYP2C9 P11712 3/20 0.36
ALDH1A1 P00352 5/20 0.36
KMT2A Q03164 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MGMT P16455 2/20 0.35
MAPT P10636 4/20 0.34
MAPK1 P28482 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MEN1 O00255 2/20 0.33
LMNA P02545 1/20 0.33
THRB P10828 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
PIK3CD O00329 1/20 0.32
AKT1 P31749 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32
POLB P06746 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9761856 0.77 KMT2A (0.40) CYP1A2CYP2C9ALDH1A1KMT2ASMN1; SMN2
SCHEMBL9761268 0.77 CYP1A2 (0.37) CYP1A2CYP2C9ALDH1A1KMT2ASMN1; SMN2
SCHEMBL9761621 0.76 CYP1A2 (0.39) CYP1A2CYP2C9ALDH1A1KMT2ASMN1; SMN2
SCHEMBL9761212 0.74 PARP1 (0.36) CYP1A2CYP2C9ALDH1A1KMT2ASMN1; SMN2
SCHEMBL9761376 0.74 MAPT (0.35) ALDH1A1KMT2AMAPTMEN1LMNA
SCHEMBL9762560 0.72 PIK3CB (0.49) CYP1A2CYP2C9ALDH1A1KMT2ASMN1; SMN2
SCHEMBL9762538 0.71 SMN1; SMN2 (0.38) CYP1A2CYP2C9ALDH1A1SMN1; SMN2MAPT
SCHEMBL9761459 0.70 ALDH1A1 (0.39) CYP1A2CYP2C9ALDH1A1KMT2ASMN1; SMN2
SCHEMBL9762175 0.69 MAPT (0.33) ALDH1A1MAPTLMNA
SCHEMBL9762150 0.68 KMT2A (0.48) CYP1A2CYP2C9ALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5026694-A Antitumor agents THE BRITISH COLUMBIA CANCER FOUNDATION (CA) 1991-06-25 US disclosed